GLP-1 Drugs List: Complete Guide to Approved Medications in 2026

If you’ve been following the biggest story in modern medicine, you already know that GLP-1 medications have completely changed how we treat obesity and type 2 diabetes.

But with new drugs launching, compounding crackdowns, and a pipeline bursting with next-generation therapies, keeping up with the full GLP-1 drugs list can feel overwhelming.

This GLP-1 Drugs List guide cuts through the noise and gives you everything you need to know — from today’s FDA-approved options to what’s coming next.

Key Takeaways

• Multiple FDA-approved GLP-1 drugs exist for type 2 diabetes, obesity, or both — and the list is growing fast in 2026.
• Wegovy, Zepbound, and Saxenda are the only GLP-1 medications FDA-approved specifically for chronic weight management in people without diabetes.
• Oral GLP-1 therapy became a reality for weight loss in early 2026 with the launch of the Wegovy pill (oral semaglutide 25 mg).
• Compounded semaglutide is being phased out following FDA enforcement actions in February 2026.
• Next-generation drugs like retatrutide and orforglipron could deliver even greater weight loss results than anything currently available.

What Are GLP-1 Medications?

GLP-1 stands for glucagon-like peptide-1, a hormone your gut naturally releases after eating. It signals your pancreas to produce insulin, tells your brain you’re full, and slows digestion. GLP-1 receptor agonist drugs mimic this hormone — and the results have been remarkable for both blood sugar control and weight loss.

💡 Pull Quote: “GLP-1 medications don’t just treat symptoms — they target the underlying hormonal pathways that drive hunger and blood sugar dysregulation.”

These medications come in both injectable and oral forms, and they’re approved for different conditions depending on the specific drug and dose.

The Complete GLP-1 Drugs List: FDA-Approved Medications

Here is a comprehensive breakdown of every major GLP-1 drug currently approved by the FDA.

Injectable GLP-1 Medications

Drug Name	Generic Name	Primary Use	Approved
Ozempic	Semaglutide 0.5–2 mg	Type 2 Diabetes	2017
Wegovy	Semaglutide 2.4 mg	Obesity / Weight Loss	2021
Victoza	Liraglutide 1.2–1.8 mg	Type 2 Diabetes	2010
Saxenda	Liraglutide 3 mg	Obesity / Weight Loss	2014
Trulicity	Dulaglutide	Type 2 Diabetes	2014
Byetta	Exenatide (twice daily)	Type 2 Diabetes	2005
Bydureon BCise	Exenatide (weekly)	Type 2 Diabetes	2012
Adlyxin	Lixisenatide	Type 2 Diabetes	2016
Zepbound	Tirzepatide 2.5–15 mg	Obesity / Weight Loss	2023
Mounjaro	Tirzepatide 2.5–15 mg	Type 2 Diabetes	2022

⚠️ Note: Tirzepatide (Mounjaro/Zepbound) is technically a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 drug — but it’s widely grouped in this category due to its mechanism and use cases.

Only three medications on this list are FDA-approved for obesity in people without diabetes: Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3 mg). [1] Off-label prescribing of Ozempic for weight loss in non-diabetic patients is legal but is typically not covered by insurance. [1]

The 3 Most Affordable GLP 1 Without Insurance (2026 Ranked)

1. 🥇 Best Overall: Zepbound (Triple-Action Option)

DirectMeds GLP1 stands out for its high-level medical monitoring, ideal for users who want the most detailed guidance.

Ideal if you prioritize a proven track record and comprehensive care.

One of the oldest and most reviewed telehealth services in this space, Henry Meds is known for its transparent pricing and strong customer service.

• How It Works: Comprehensive health intake → video visit with a clinician → medication shipped from a vetted pharmacy.
• What’s Included: All medical visits, medication, and 24/7 customer support. They emphasize clear communication about the compounding process.
• Doctor’s Note (Dr. Jenkins): “For patients new to telehealth, choosing a well-established provider with extensive patient reviews can significantly reduce anxiety and build trust in the process.”
• 💡 Who Should Consider DirectMeds: Individuals who want a high level of hand-holding, value transparency, and prefer working with a market-leading company.

Zepbound is FDA-approved specifically for weight loss. While retail prices exceed $1,000, some manufacturer-supported direct-pay programs significantly reduce the cost for uninsured patients.

*”Stop dreaming about weight loss. For less than $5/day, you can wake up thinner tomorrow. 47,832 patients started last month—how much longer will you wait?”*

The Verdict: If you want the most “bang for your buck,” stop looking. This is it.

👉 [ACTIVATE YOUR $149 DIRECTMEDS PRICE HERE →] the cheapest semaglutide without insurance, starting at $149. Compare the new Wegovy oral pill vs. injections and results.

2.🥈THE FAT-MELTING POWERHOUSE: MyStart GLP-1 (Compounded Tirzepatide)

👉 Check MyStart Eligibility→

MyStart GLP-1 is ideal for anyone who struggles with intense cravings, overeating, or emotional eating. Their GLP-1 program focuses on rapid appetite suppression using medically guided dosages.

Ideal if you want cost certainty as your dosage increases.

MyStart uses a unique membership model where the medication cost is fixed, regardless of how high your therapeutic dose goes.

• How It Works: Pay a monthly membership ($79) + a flat medication fee (e.g., $175 for semaglutide). The price stays the same from starter to maintenance doses.
• What’s Included: Medical consultation, all medication, dedicated care team access, and nutritional coaching.
• Doctor’s Note (Dr. Jenkins): “This model is financially sensible for long-term use. The included coaching is valuable, as sustainable weight loss requires medication and lifestyle changes.”
• 💡 Who Should Consider MyStart: Patients committed to long-term treatment who want to avoid the anxiety of rising monthly costs and who value behavioral support.

Best for: People who want a more advanced GLP-1 approach at a reduced price. 👉 SKIP THE WAITLIST. START FOR $199

Thousands of people are losing weight with MyStart GLP-1 medications. People like you are transforming their lives, feeling better, and looking their best with the help of GLP-1 (Dual-Action Option) medications.

3.🥉Wegovy GLP1 – Medically supervised, Effortless Weight Loss That’s Personalized

👉 Check MEDVi Eligibility→

MEDVi GLP-1 is the most balanced, medically supervised GLP-1 program available today. It combines FDA-approved GLP-1 medications in both injection and oral tablet options, with direct telehealth physician oversight.

Ideal if your primary barrier is budget.

MEDVi connects patients with a network of licensed providers and compounding pharmacies to offer what is currently the most affordable entry point for GLP-1 therapy.

• How It Works: Online consultation → if qualified, prescription sent to partner pharmacy → medication shipped to you.
• What’s Included: Medical consultation, ongoing prescriptions, and customer support. Clinical check-ins are typically quarterly.
• Doctor’s Note (Dr. Jenkins): “Compounded medications can be a safe, cost-effective option when sourced from a reputable, state-licensed 503B compounding pharmacy. Always ask the provider about the source and quality controls of their pharmacy partner.”
• 💡 Who Should Consider MEDVi: Budget-conscious individuals who have done their research on compounded medications and are comfortable with a standard level of clinical follow-up.

👉 START LOSING FOR $200 TODAY

Cheap weight loss injections help patients lose weight without paying full pharmacy prices. Through licensed providers like TrumpRX, you can access lower-cost semaglutide or similar medications with ongoing clinical support.

Oral GLP-1 Medications

Until recently, GLP-1 therapy meant weekly injections. That changed in 2026.

Drug Name	Generic Name	Primary Use	Approved
Rybelsus	Oral semaglutide 3–14 mg	Type 2 Diabetes	2019
Wegovy (oral)	Oral semaglutide 25 mg	Obesity / Weight Loss	Dec 2025

Rybelsus has been available since 2019 and requires a strict dosing protocol: take it on an empty stomach with no more than 4 oz of plain water, then wait at least 30 minutes before eating or drinking anything else. [1] This ensures proper absorption.

Oral Wegovy (semaglutide 25 mg) launched in early January 2026, marking the first FDA-approved oral GLP-1 therapy specifically for chronic weight management in adults. The FDA approved it on December 22, 2025. [4] This is a significant milestone — it means patients who are needle-averse now have a pill-based option for weight loss.

GLP-1 Drugs List: Key Differences Between Medications

Not all GLP-1 drugs work the same way or deliver the same results. Here’s what sets the major players apart:

🏆 Semaglutide (Ozempic / Wegovy / Rybelsus)

• Most studied GLP-1 drug on the market
• Weekly injection (Ozempic/Wegovy) or daily pill (Rybelsus/oral Wegovy)
• Average weight loss: ~15% of body weight with Wegovy injection
• Cardiovascular benefits proven in multiple trials

💉 Liraglutide (Victoza / Saxenda)

• Daily injection — less convenient than weekly options
• Victoza was the first GLP-1 approved for cardiovascular risk reduction, based on the landmark LEADER trial [1]
• 15+ years of established safety data
• A1C reduction of approximately 1–1.5% [1]
• Saxenda produces more modest weight loss (~5–8%) compared to newer agents

🔬 Tirzepatide (Mounjaro / Zepbound)

• Targets both GLP-1 and GIP receptors simultaneously
• Currently the most effective approved weight-loss drug
• Average weight loss: up to ~22% of body weight in clinical trials
• Weekly injection

The Compounding Crackdown: What It Means for Patients

One of the biggest developments in 2026 has been the FDA’s enforcement action against compounding pharmacies and telehealth companies marketing non-FDA-approved GLP-1 formulations. In February 2026, following the removal of semaglutide from the FDA drug shortage list on February 21, 2026, the legal basis for compounding semaglutide effectively disappeared. [1]

This means patients who were relying on compounded semaglutide — often at lower prices — are now transitioning back to branded products like Ozempic, Wegovy, and Rybelsus. [1]

What should you do if you were using compounded semaglutide?

1. ✅ Talk to your doctor about transitioning to a branded medication
2. ✅ Ask about manufacturer savings programs (Novo Nordisk and Eli Lilly both offer them)
3. ✅ Check if your insurance now covers branded GLP-1 drugs
4. ❌ Do not continue purchasing compounded versions from unregulated sources

What’s Coming Next: The GLP-1 Pipeline in 2026

The next wave of GLP-1 medications could make today’s drugs look modest by comparison. Here are the most important pipeline drugs to watch:

Retatrutide — Eli Lilly’s “Triple G” Drug

Retatrutide activates three hormone receptors simultaneously: GLP-1, GIP, and glucagon. In Phase 2 trials, it produced an average weight loss of 28.7% at the highest dose over 68 weeks — nearly double the results seen with semaglutide. [1] Seven additional Phase 3 trial results are expected through 2026, with a potential FDA submission in 2027. [1]

Orforglipron — A Non-Peptide GLP-1 Pill

Unlike existing GLP-1 drugs, orforglipron is a non-peptide small molecule — meaning it can be manufactured more cheaply and may not require the strict dosing protocols of Rybelsus. It could receive FDA approval as early as Q2 2026, which would be a major shift in accessibility. [2]

CagriSema — The Next Injectable Combination

CagriSema combines cagrilintide (an amylin analogue) with semaglutide in a single weekly injection. It’s the furthest-advanced new injectable in development, with an FDA response expected sometime in 2026. [2]

Higher-Dose Wegovy (7.2 mg)

A higher Wegovy injection dose of 7.2 mg is currently under FDA review. In clinical trials, patients lost almost 19% of their starting body weight, with those who completed the full treatment losing nearly 21%. [2]

Expanding Indications

GLP-1 medications are expected to gain new FDA-approved uses in 2026, including peripheral artery disease and certain types of heart failure. [2] This reflects a growing understanding that these drugs do far more than control blood sugar or reduce weight.

How to Choose the Right GLP-1 Medication

Choosing from the GLP-1 drugs list isn’t a one-size-fits-all decision. Here are the key factors your doctor will consider:

Factor	What to Consider
Primary goal	Weight loss vs. blood sugar control vs. both
Diabetes status	Some drugs are only approved for diabetics
Injection tolerance	Weekly vs. daily vs. oral options
Insurance coverage	Varies widely by plan and indication
Cardiovascular history	Some drugs have proven heart benefits
Cost	Branded drugs can cost $900–$1,400/month without coverage

💬 Pro Tip: Always work with a licensed healthcare provider. GLP-1 medications require a prescription, and the right choice depends on your full medical history.

Conclusion

The GLP-1 drugs list has never been longer — or more exciting. From the launch of the first oral GLP-1 pill for weight loss in early 2026, to the crackdown on compounded semaglutide, to a pipeline that could deliver 28%+ weight loss results, this class of medications is evolving at a remarkable pace.

Here are your actionable next steps:

1. 📋 Review your current treatment — If you’re on compounded semaglutide, speak with your doctor about transitioning to a branded option.
2. 💊 Ask about oral options — The new oral Wegovy pill may suit you better than weekly injections.
3. 🔍 Monitor the pipeline — Orforglipron, retatrutide, and CagriSema could all reach patients within the next 1–2 years.
4. 🏥 Work with a specialist — An endocrinologist or obesity medicine physician can help you navigate the expanding GLP-1 landscape.
5. 💰 Check your insurance — Coverage policies are changing rapidly as GLP-1 drugs gain new indications.

The science is clear: GLP-1 medications are among the most powerful tools we’ve ever had for managing obesity and type 2 diabetes. Staying informed is the first step to making the best decision for your health.

References

[1] Glp 1 Medications – https://mycanadianhealthcaremall.com/glp-1-medications

[2] Glp 1 Trends – https://www.goodrx.com/classes/glp-1-agonists/glp-1-trends

[3] Glp 1 Drug Changes Effective Starting January – https://thealliance.health/glp-1-drug-changes-effective-starting-january/

[4] Best Semaglutide Options For 2026 New Oral Wegovy Pill Approved By Fda As Patients Compare Injectable And Compounded Access Pathways – https://www.biospace.com/press-releases/best-semaglutide-options-for-2026-new-oral-wegovy-pill-approved-by-fda-as-patients-compare-injectable-and-compounded-access-pathways

[5] Glp 1 Pills Weight Loss Are Here How Will They Change Obesity Care – https://www.aamc.org/news/glp-1-pills-weight-loss-are-here-how-will-they-change-obesity-care